Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. (Q46623103)

From Wikidata

Jump to navigation Jump to search

scientific article published on 25 April 2008

Language	Label	Description	Also known as
English	Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.	scientific article published on 25 April 2008

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18441330%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18441330%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18441330%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

author name string

T Höhler

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18441330%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

C Dittrich

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18441330%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

F Lordick

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18441330%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

T Seufferlein

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18441330%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

J Riemann

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18441330%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

E Wöll

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18441330%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

T Herrmann

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18441330%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

A Zubel

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18441330%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

H-J Schmoll

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18441330%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

publication date

25 April 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18441330%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18441330%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18441330%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18441330%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1442-1449

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18441330%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN150

21 January 2018

Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN150

21 January 2018

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN150

21 January 2018

Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN150

21 January 2018

Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN150

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN150

21 January 2018

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN150

21 January 2018

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN150

21 January 2018

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN150

21 January 2018

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN150

21 January 2018

Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN150

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN150

21 January 2018

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN150

21 January 2018

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN150

21 January 2018

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN150

21 January 2018

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN150

21 January 2018

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN150

21 January 2018

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN150

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46623103&oldid=1409274045"